Review Article

Translocator Protein 18kDa (TSPO) as a Novel Therapeutic Target for Chronic Pain

Jie Liu, Jingyao Huang, Zhenjiang Zhang, Rui Zhang, Zhihao Zhang, Yongxin Liu, and Baoyu Ma

1Shandong Provincial Medicine and Health Key Laboratory of Clinical Anesthesia, School of Anesthesiology, Weifang Medical University, Weifang, China
2Department of Thoracic Surgery, Weifang People’s Hospital, Weifang, China

Correspondence should be addressed to Rui Zhang; zhangrui@wfmc.edu.cn

Received 11 April 2022; Revised 19 July 2022; Accepted 13 August 2022; Published 29 August 2022

Academic Editor: Xue-Qiang Wang

Copyright © 2022 Jie Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chronic pain is an enormous modern public health problem, with significant numbers of people debilitated by chronic pain from a variety of etiologies. Translocator protein 18 kDa (TSPO) was discovered in 1977 as a peripheral benzodiazepine receptor. It is a five transmembrane domain protein, mainly localized in the outer mitochondrial membrane. Recent and increasing studies have found changes in TSPO and its ligands in various chronic pain models. Reversing their expressions has been shown to alleviate chronic pain in these models, illustrating the effects of TSPO and its ligands. Herein, we review recent evidence and the mechanisms of TSPO in the development of chronic pain associated with peripheral nerve injury, spinal cord injury, cancer, and inflammatory responses. The cumulative evidence indicates that TSPO-based therapy may become an alternative strategy for treating chronic pain.

1. Introduction

Chronic pain is a major public health issue, which seriously affects patients’ quality of life and aggravates economic burdens on society. According to the International Association for the Study of Pain (IASP), chronic pain can be categorized as chronic primary pain and chronic secondary pain, (e.g., chronic cancer-related pain, chronic postoperative or post-traumatic pain, and chronic neuropathic pain) [1]. Opioids are powerful analgesics that are commonly used clinically. However, opioids can produce significant side effects, including respiratory depression, mental clouding, physical dependence, constipation, nausea, and vomiting [2, 3]. Despite increasing investigations into chronic pain mechanisms and therapeutic strategies [4, 5], current therapies for chronic pain management are severely insufficient or, as in the case of opioids, limited by serious side effects [6]. Therefore, exploring novel and effective analgesics for chronic pain treatment is crucial.

The translocator protein 18 kDa (TSPO) was discovered in 1977 as a peripheral benzodiazepine receptor [7]. This mitochondrial protein consists of 169 amino acids with five transmembrane domains [8], which is mainly localized in the outer mitochondrial membrane (OMM) [9]. TSPO can interact with specific mitochondrial proteins, like voltage-dependent anion channel (VDAC) and anion nucleotide translocator (ANT) [10–12], which are involved in the composition of mitochondrial permeability translocation pores and regulate development of physiological and pathological conditions [13], suggesting the key role of TSPO in cellular functions related to mitochondria. TSPO was initially designated as a peripheral-type benzodiazepine receptor, which is the binding site for benzodiazepines used to treat patients with anxiety, convulsions, or insomnia [7]. However, further research has shown that TSPO is widely expressed in most organs within the body, including the secretory and glandular tissues, kidney, heart, liver, and brain [8, 14, 15]. Its widespread distribution is consistent with its diverse
physiological functions, including membrane biogenesis, heme biosynthesis, redox balance, bioenergetics, cell proliferation, apoptosis, immunomodulation, and cholesterol binding and transport [8, 9, 16–20]. In the nervous system, TSPO has been investigated as a biomarker for various neuropathologies [21]. Recently, TSPO and its ligands have been found to be effective in neurodegeneration [22], neuroinflammation [23], and neuropathic pain [24]. These studies highlight the potential uses of TSPO and its ligands for neuroprotection, limiting neuroinflammation, promoting regeneration, and treating nervous system dysfunctions. Herein, we review the current evidence for the role of TSPO and its ligands in the development of chronic pain, including neuropathic pain, cancer pain, and inflammatory pain (Table 1) [24–26].

2. Possible Mechanisms of TSPO in Pain Processing

The mechanisms of chronic pain development involve a variety of factors, among which neuroinflammation is an important mechanism resulting in this process [8]. Glia cells, through interactions with neurons via transmitters, cytokines, or chemokines, participate in neuroinflammation [45]. In the spinal nerve ligation (SNL) model, microglia release chemokine CXC motif ligand 1 (CXCL1); its transport to neurons results in neuroinflammation, promoting the development of chronic pain [27]. After chronic complete Freund’s adjuvant (CFA) injections, interleukin-6 (IL-6) released from activated astrocytes can also activate neurons by promoting neuroinflammation, resulting in chronic pain [25]. These results indicated the role of glia in neuroinflammation and chronic pain.

TSPO is upregulated concomitant with microglial activation, and strong colocalization between TSPO upregulation and activated microglia has been found during neuroinflammation in various disorders, including neurodegeneration [46], peripheral nervous system lesions [47], and brain damage [48]. Hence, TSPO has served as a marker of microglial activation and neuroinflammation and as a predictor of chronic pain in disorders like fibromyalgia [49] and neuropathic pain [33]. Recently, TSPO was reported to participate in neuropathic pain [50], and it was shown that the TSPO-positive allosteric modulator koumine alleviates inflammation and neuropathic pain by modulating microglial activation and polarization, along with astrocyte activation [30, 50]. Wei et al. [24] found that the agonistic TSPO ligands Ro5-4864 and FGln1-1,27 decrease tumor necrosis factor-α (TNF-α) levels released by spinal activated astrocytes, alleviating neuroinflammation in a rat chronic pain model. Thus, in addition to serving as a marker for activated microglia and neuroinflammation, TSPO plays a protective role in neuroinflammation, which may inhibit chronic pain.

TSPO may also participate in the development of chronic pain by mediating the synthesis of neurosteroids [51]. Neurosteroids play important roles in the structure and function of the nervous system [51], including inflammation, synaptic transmission, pain, consciousness, and cognition [52]. Numerous studies have shown that maintaining the normal structure and function of the nervous system is essential for preventing chronic pain development [11]. Neurosteroids are a class of steroid hormones that are widely distributed in the central and peripheral nervous systems [53]. TSPO transports cholesterol from the cytoplasm to the mitochondria, after which the cholesterol entering the mitochondria is catalyzed by a series of enzymes to produce steroid hormones [54]. This role of TSPO for steroid hormone synthesis is thus rate-limiting. Coronel et al. [34] found that expressions of TSPO and steroidogenic enzyme 5α reductase (I/III), which participate in steroid hormone synthesis [55], are significantly reduced and that progesterone injections reverse TSPO expression, in spinal cord injury (SCI). This demonstrated a correlation between TSPO and steroid hormone synthesis. Another group observed an increase in thalamic steroid hormone synthesis in the chronic phase of a rat pain model, which was accompanied by increased TSPO expression. Intrathalamic administration of steroid hormone, or AC-5216 (a TSPO agonist), reduced rats’ pain symptoms; this effect was counteracted by administration of a TSPO inhibitor [56]. These studies suggest an inhibitory effect of steroid hormones on pain, and TSPO, as a rate-limiting enzyme for steroid hormone synthesis, may reduce pain by regulating neurosteroid synthesis (Figure 1).

3. The Role of TSPO in Chronic Pain

3.1. TSPO and Neuropathic Pain. The IASP defines neuropathic pain as pain caused by a lesion or disease of the somatosensory nervous system [57, 58]. Neuropathic pain is characterized by abnormal hypersensitivity to noxious stimuli (hyperalgesia) and abnormal pain responses to non-noxious stimuli (allodynia) [59]. A-δ fiber and C-fiber primary afferent neurons in the peripheral nervous system transport pain signals to the central nervous system. Peripheral nerve injury (PNI) can activate sensitized neurons in these fibers. The latter also produce continuous pain stimulation signals [60], which can then transport to the dorsal horn of the spinal cord, further promoting central sensitization. Various animal models have been used to explore the mechanisms of neuropathic pain in PNI, SCI, and diabetes [61]. A growing volume of recent evidence indicates that TSPO plays a critical role in neuropathic pain.

3.1.1. TSPO and Peripheral Nerve Injury. Many studies have used animal models of PNI to explore novel strategies attenuating neuropathic pain and nerve regeneration. In early studies, TSPO improved peripheral nerve regeneration and functional recovery after nerve lesions [22, 28]. Daily intraperitoneal injections (i.p.) of etifoxine, an agonistic TSPO ligand, can promote axonal regeneration and improve functional recovery in rats with sciatic nerve injury (SNI) [22]. Another agonistic TSPO ligand, Ro5-4864, can substantially enhance adult facial motor neuron nerve regeneration and restore function after facial nerve axotomy [28]. In nerve stumps of SNI model rats, interleukin-1β (IL-1β) and IL-6 mRNA levels are significantly upregulated, while etifoxine treatment limits their increase in the proximal stumps [22].
### Table 1: Role of TSPO and its ligands in chronic pain.

| Model            | TSPO/ligand | Mechanism                                                                 | Reference(s) |
|------------------|-------------|---------------------------------------------------------------------------|--------------|
| SNL              | TSPO        | Inhibit CXCL1-CXCR2-dependent astrocyte-to-neuron signaling and central sensitization | [24, 27]     |
|                  | Ro5-4864    | Downregulate expression of TNF-α; alleviate mechanical allodynia and thermal hyperalgesia | [27, 28]     |
| FGIN-1-27        |             | Downregulate expression of TNF-α, alleviate mechanical allodynia and thermal hyperalgesia | [27, 28]     |
| CCI              | Koumine     | Downregulate the expression of TNF-α and IL-1β; inhibit microglia and astrocyte activation | [29, 30]     |
| SNI              | Ro5-4864    | Downregulate the expression of p-ERK1/2 and BDNF in DRG; improve axonal regeneration and functional recovery | [31, 32]     |
| PK11195          |             | Assess the role of glial activation                                        | [33]         |
| SCI              | ZBD-2       | Inhibit chronic activation of microglia and astrocytes; alleviate mechanical allodynia and thermal hyperalgesia | [34, 35]     |
| CIBP             | Progesterone| Reduce spinal expression of proinflammatory enzymes and cytokines         | [36, 37]     |
| CFA-induced      | MZL         | Inhibit the IL-6/IL-6R trans-signaling pathway and MAPK ERK pathway; alleviate thermal hyperalgesia | [39, 40]     |
| Monoarthritic    | Ro5-4864    | Alleviate mechanical allodynia and thermal hyperalgesia                   | [41–43]      |

SNL: spinal nerve ligation; CCI: chronic constriction injury; SNI: sciatic nerve injury; SCI: spinal cord injury; CIBP: cancer-induced bone pain; CFA: Freund’s adjuvant; TSPO: translocator protein; ZBD-2: N-benzyl-N-ethyl-2-(7,8-dihydro-7-benzyl-8-oxo-2-phenyl-9H-purin-9-yl) acetamide; MZL: midazolam; CXCL1: chemokine CXC motif ligand 1; CXCR2: chemokine CXC motif receptor 2; TNF-α: tumor necrosis factor-α; BDNF: brain-derived neurotrophic factor; DRG: dorsal root ganglion.

**Figure 1**: Mechanisms by which TSPO and its ligands inhibit chronic pain. (a, b) TSPO and its ligands inhibit microglial and astrocyte activation, thereby inhibiting activation-mediated central sensitization and chronic pain. (c) TSPO and its ligands inhibit chronic pain by mediating neurosteroid synthesis. (d) TSPO and its ligands promote cholesterol transport from the cytoplasm to the mitochondrial inner membrane, mediating progesterone synthesis and thus promoting neurosteroid synthesis. TSPO: translocator protein; IMM: inner mitochondrial membrane; OMM: outer mitochondrial membrane; VDAC: voltage-dependent anion channel; ANT: adenine nucleotide transporter.
These inflammatory cytokine changes indicate that TSPO ligands can influence inflammation in the peripheral nerve. In recent years, investigators have focused on the role of neuroinflammation in neuropathic pain induced by PNI, many of whom have evaluated the influence of TSPO-mediated anti-inflammation in this condition. TSPO expression is significantly increased in a L5 SNL rat model [24], and a single intrathecal injection of TSPO agonist Ro5-4864 or FG1N-1-27 alleviates the established mechanical allodynia and thermal hyperalgesia. Subsequently, upregulated TSPO was decreased when neuropathic pain healed naturally followed by administration of these agonists. This phenomenon may explain that TSPO might promote recovery from a neuropathic pain state. Enzyme-linked immunosorbent assay work has revealed that increased TNF-α, a proinflammatory cytokine, in the spinal dorsal horn is suppressed after Ro5-4864 treatment. Further, early upregulation of TSPO in astrocytes of the spinal dorsal horn partly inhibit chemokine CXC motif ligand 1-chemokine CXC motif receptor 2- (CXCL1-CXCR2-) dependent astrocyte-to-neuron signaling and central sensitization, eliciting potent analgesic effects against chronic neuropathic pain induced by SNL [27]. These studies cumulatively suggest that TSPO agonists can inhibit neuroinflammation induced by proinflammatory cytokines or chemokines in a SNL model against chronic neuropathic pain.

Proinflammatory cytokines TNF-α and IL-1β participate in neuropathic pain in a chronic constriction injury (CCI) model [29]. Jin et al. [30] described TSPO’s inhibitory effects on increased levels of these two proinflammatory cytokines and CCI-evoked microglial and astrocyte activation, in the spinal cord of a rat CCI model using koumine, a potential agonist. Further, TSPO was activated in neurons of the rat dorsal root ganglion (DRG) after spared nerve injury [31], and a single intrathecal injection of Ro5-4864 exerts remarkable analgesic effect in a SNL model. Western blotting shows that increased levels of phospho-extracellular signal-regulated kinase 1/2 (p-ERK1/2) and brain-derived neurotrophic factor (BDNF) in the DRG are inhibited after Ro5-4864 injection. Activation of the ERK1/2 signaling pathway and its downstream BDNF in DRG neurons also participate in the development of neuropathic pain after PNI via peripheral inflammation [32]. In that study, all increased levels of activated TSPO were suppressed or returned to normal after neuropathic pain healing, indicating that the role of TSPO upregulation may be to induce this recovery. The mechanism of its inhibition effect may be also involved in anti-neuroinflammatory processes, in neuropathic pain patients [33]. Recent reports suggest that TSPO can improve chronic SCI-induced neuropathic pain [34, 35]. Li et al. found that intragastric administration of ZBD-2 (N-benzyl-N-ethyl-2-(7,8-dihydro-7-benzyl-8-oxo-2-phenyl-9H-purin-9-yl) acetamide), an agonistic TSPO ligand, markedly reduces mechanically induced allodynia and thermal hyperalgesia in a SCI model [35]. Immunohistochemistry and western blot data suggest reversed effects of ZBD-2 on chronic activation of microglia and astrocytes after SCI, further explaining the relationship between TSPO and neuroinflammation.

Liu et al. [34] also found an effect of TSPO in SCI through another mechanism: the steroid hormone progesterone. This hormone activated TSPO, downregulating mechanical and thermal allodynia in a SCI model. Progesterone administration can also reduce expression of proinflammatory enzymes and cytokines in chronic neuropathic pain [36, 37], suggesting a potential role of progesterone in TSPO and neuroinflammation. These findings suggest that TSPO and its ligands may be potential targets for the treatment of SCI-associated neuropathic pain.

3.2. TSPO and Cancer Pain. Chronic pain is among the most common, burdensome, and feared cancer complications [64]. Many patients with advanced cancer experience severe pain, for which adequate analgesia strategies, without unacceptable side effects, remain a clinical challenge [65, 66]. Despite concomitant neuropathic and inflammatory pain, cancer pain’s additional distinctive characteristics include metastatic cancer-induced bone pain [67]. Increased attention has been paid to investigating the role of neuroinflammation in cancer pain [68]. Herein, we focus on the anti-inflammation effects of TSPO in chronic pain from bone metastasis. TSPO level is increased in both astrocytes and microglia of a rat model for bone cancer pain (BCP) [26]. Further, a single intrathecal administration of midazolam (MZL), an agonistic TSPO ligand [38], can inhibit thermal hyperalgesia in BCP rats via spinal activation of TSPO. Increased expression of the inflammatory cytokine IL-6 is decreased after MZL injection. IL-6 is considered a trigger for the initiation and maintenance of chronic pain [38]. In the BCP model, IL-6 expression increased in the DRG and spinal cord [26, 39]. Remarkably, Fang et al. attenuated bone cancer-induced hyperalgesia in BCP rats by inhibiting the IL-6/sIL-6R trans-signaling pathway, implicating IL-6 in the development of BCP [39]. Increased IL-6 expression was decreased after MZL injection, indicating that TSPO may play a protective role in bone cancer-induced inflammation. Furthermore, the spinal MAPK ERK pathway, which participates in neuroinflammation [40], was inhibited in MZL-attenuated thermal hyperalgesia in BCP rats. These changes in two inflammation mediators indicate that glial TSPO may be a potential target for bone cancer-induced neuroinflammation.

3.3. TSPO and Inflammatory Pain. Inflammatory pain is the most important clinical symptom of inflammatory diseases. It can severely impact the quality of life among patient, suffering from osteoarthritis (OA), rheumatoid arthritis, and other diseases [25]. Prolonged inflammatory pain can lead to...
activation of spinal microglia and astrocytes [69]. Investigators have explored whether increased TSPO can serve as a marker of nervous system activation in an OA pain model, for use in predicting development of chronic pain using novel PBR/TSPO imaging agents [70–72]. In recent animal inflammatory pain models, TSPO was identified as playing anti-inflammation and antinociception roles in chronic pain. To build a CFA-induced monoarthritic model, rats were injected with CFA into the right tibiotarsal joint [25]; intra-articular CFA injection reliably induced thermal hyperalgesia and mechanical allodynia, and spinal TSPO expression was increased in neurons, astrocytes, and microglia, implying activated nervous system activity. Furthermore, intrathecal TSPO agonist (Ro5-4864) administration dose-dependently inhibited CFA-induced mechanical allodynia and thermal hyperalgesia. A similar anti-inflammatory effect was detected in formalin-induced chronic pain and ATP-induced NLRP3 inflammasome activation [41, 44]. A previous study also found that treatment with a TSPO ligand can downregulate proinflammatory mediator IL-1β expression and activate the NLRP3 inflammasome [41]. Spinal IL-1β can play an important role in formalin- and CFA-induced inflammatory pain [42, 43]. These cumulative findings suggest that TSPO may play an anti-inflammatory effect by mediating the release of these proinflammation cytokines, exerting part of their antinociceptive effects on inflammatory pain.

4. Conclusions

In this review, we reviewed the relations between TSPO and chronic pain. Cumulative findings have clarified that TSPO plays a vital role in alleviating the initiation and maintenance of chronic pain, including neuropathic pain, inflamatory pain, and cancer pain. Although TSPO expression is increased under inflammatory conditions [73, 74], it acts as a negative regulator of inflammation [75]. In the studies described herein, expression of proinflammation factors like IL-1β, IL-6, and CXCL1 is decreased after overexpression or activation of TSPO, further validating the role of TSPO in the inhibition of the neuroinflammatory response. Although the mechanisms of TSPO’s effective role in nerve diseases has been validated through clinical trials [76], the clinical effects of TSPO as an agent for alleviating chronic pain have not yet been explored. However, the preclinical TSPO studies described herein provide novel insight that may facilitate drug development to advance pain therapies. Further clinical trials will now be needed to explore the effects of TSPO treatment for pain alleviation.
Conflicts of Interest

All authors have no competing interests.

Acknowledgments

This work was supported by the Natural Science Foundation of Shandong Province (ZR2017MH066), the Weifang Science and Technology Development Program Project (No. 2019YX005), and the Shandong Medical and Health Technology Development Program (No. 202104020452).

References

[1] R. D. Treede, W. Rief, A. Barke et al., “Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11),” *Pain*, vol. 160, no. 1, pp. 19–27, 2019.

[2] T. Abijo, K. Blum, and M. C. Gondre-Lewis, “Neuropharmacological and neurogenetic correlates of opioid use disorder (OUD) as a function of ethnicity: relevance to precision addiction medicine,” *Current Neuropharmacology*, vol. 18, no. 7, pp. 578–595, 2020.

[3] D. Q. Liu, Y. Q. Zhou, and F. Gao, “Targeting cytokines for morphine tolerance: a narrative review,” *Current Neuropharmacology*, vol. 17, no. 4, pp. 366–376, 2019.

[4] Y. Q. Zhou, D. Q. Liu, S. P. Chen et al., “Cellular and molecular mechanisms of calcium/calmodulin-dependent protein kinase II in chronic pain,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 363, no. 2, pp. 176–183, 2017.

[5] S. Liu, Y. P. Liu, Y. Lv et al., “IL-18 contributes to bone cancer pain by regulating glia cells and neuron interaction,” *The Journal of Pain*, vol. 19, no. 2, pp. 186–195, 2018.

[6] E. Coppi, F. Cherchi, E. Lucarini et al., “Uncovering the mechanisms of adenosine receptor-mediated pain control: focus on the A3 receptor subtype,” *International Journal of Molecular Sciences*, vol. 22, no. 15, p. 7952, 2021.

[7] C. Braestrup and R. F. Squires, “Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H) diazepam binding,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 74, no. 9, pp. 3805–3809, 1977.

[8] V. Papadopoulos, M. Baraldi, T. R. Gualtiero et al., “Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function,” *Trends in Pharmacological Sciences*, vol. 27, no. 8, pp. 402–409, 2006.

[9] L. J. Motloch, J. Hu, and F. G. Akar, “The mitochondrial translocator protein and arrhythmogenesis in ischemic heart disease,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 234104, 8 pages, 2015.

[10] M. W. McEnery, A. M. Snowman, R. R. Trifiletti, and S. H. Snyder, “Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 89, no. 8, pp. 3170–3174, 1992.

[11] M. Garnier, A. B. Dimchev, N. Boujrad, J. M. Price, N. A. Musto, and V. Papadopoulos, “In vitro reconstitution of a functional peripheral-type benzodiazepine receptor from mouse Leydig tumor cells,” *Molecular Pharmacology*, vol. 45, no. 2, pp. 201–211, 1994.

[12] L. Veenman, Y. Shandalov, and M. Gavish, “VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis,” *Journal of Bioenergetics and Biomembranes*, vol. 40, no. 3, pp. 199–205, 2008.

[13] J. Gatiff and M. Campanella, “TSPO: kaleidoscopic 18-kDa amid biochemical pharmacology, control and targeting of mitochondria,” *The Biochemical Journal*, vol. 473, no. 2, pp. 107–121, 2016.

[14] A. Batarseh and V. Papadopoulos, “Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states,” *Molecular and Cellular Endocrinology*, vol. 327, no. 1-2, pp. 1–12, 2010.

[15] C. GiatZakis and V. Papadopoulos, “Differential utilization of the promoter of peripheral-type benzodiazepine receptor by steroidogenic versus nonsteroidogenic cell lines and the role of Sp1 and Sp3 in the regulation of basal activity,” *Endocrinology*, vol. 145, no. 3, pp. 1113–1123, 2004.

[16] D. Morin, J. Musman, S. Pons, A. Berdeaux, and B. Ghaleh, “Mitochondrial translocator protein (TSPO): from physiology to cardioprotection,” *Biochemical Pharmacology*, vol. 105, pp. 1–13, 2016.

[17] J. P. Faure, H. Baumert, Z. Han et al., “Evidence for a protective role of trimetazidine during cold ischemia: targeting inflammation and nephron mass,” *Biochemical Pharmacology*, vol. 66, no. 11, pp. 2241–2250, 2003.

[18] S. Taketani, H. Kohno, M. Okuda, T. Furukawa, and R. Tokunaga, “Induction of peripheral-type benzodiazepine receptors during differentiation of mouse erythroblasts. A possible involvement of these receptors in heme biosynthesis,” *The Journal of Biological Chemistry*, vol. 269, no. 10, pp. 7527–7531, 1994.

[19] S. R. Torres, T. S. Fröde, G. M. Nardi et al., “Anti-inflammatory effects of peripheral benzodiazepine receptor ligands in two mouse models of inflammation,” *European Journal of Pharmacology*, vol. 408, no. 2, pp. 199–211, 2000.

[20] A. A. Yeliseev and S. Kaplan, “TspO of Rhodobacter sphaeroides,” *The Journal of Biological Chemistry*, vol. 275, no. 8, pp. 5657–5667, 2000.

[21] R. Rupprecht, V. Papadopoulos, G. Rammes et al., “Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders,” *Nature Reviews. Drug Discovery*, vol. 9, no. 12, pp. 971–988, 2010.

[22] C. Girard, S. Liu, F. Cadepond et al., “Etifoxine improves peripheral nerve regeneration and functional recovery,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 51, pp. 20505–20510, 2008.

[23] J. W. Lee, H. Nam, and S. W. Yu, “Systematic analysis of translocator protein 18 kDa (TSPO) ligands on toll-like receptors-mediated pro-inflammatory responses in microglia and astrocytes,” *Experimental Neurobiology*, vol. 25, no. 5, pp. 262–268, 2016.

[24] X. H. Wei, X. Wei, F. Y. Chen et al., “The upregulation of translocator protein (18 kDa) promotes recovery from neurogenic pain in rats,” *The Journal of Neuroscience*, vol. 33, no. 4, pp. 1540–1551, 2013.

[25] H. Hernstadt, S. Wang, G. Lim, and J. Mao, “Spinal translocator protein (TSPO) modulates pain behavior in rats with CFA-induced monoarthritis,” *Brain Research*, vol. 1286, pp. 42–52, 2009.

[26] C. H. Guo, L. Bai, H. H. Wu et al., “Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with...
different mechanisms in rats," *Oncology Reports*, vol. 37, no. 1, pp. 249–258, 2017.

[27] X. Liu, H. Liu, S. Xu et al., "Spinal translocator protein alleviates chronic neuropathic pain behavior and modulates spinal astrocyte-neuronal function in rats with L5 spinal nerve ligation model," *Pain*, vol. 157, no. 1, pp. 103–116, 2016.

[28] C. Mills, M. Makwana, A. Wallace et al., "Ro5-4864 promotes neonatal motor neuron survival and nerve regeneration in adult rats," *The European Journal of Neuroscience*, vol. 27, no. 4, pp. 937–946, 2008.

[29] L. W. Chu, K. I. Cheng, J. Y. Chen et al., "Loganin prevents chronic constriction injury-induced neuropathic pain by reducing TNF-α/IL-1β-mediated NF-kB activation and Schwann cell demyelination," *Phytomedicine*, vol. 67, article 153166, 2020.

[30] G. L. Jin, S. D. He, S. M. Lin et al., "Koumine attenuates neuroglia activation and inflammatory response to neuropathic pain," *Neural Plasticity*, vol. 2018, Article ID 9347696, 13 pages, 2018.

[31] B. Ma, X. Liu, X. Huang, Y. Ji, T. Jin, and K. Ma, "Translocator protein agonist Ro5-4864 alleviates neuropathic pain and promotes remyelination in the sciatic nerve," *Molecular Pain*, vol. 14, p. 174480691774801, 2018.

[32] K. Obata, H. Yamanaka, Y. Dai et al., "Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats," *The European Journal of Neuroscience*, vol. 20, no. 11, pp. 2881–2895, 2004.

[33] N. Imamoto, S. Momosaki, M. Fujita et al., "[11C]PK11195 PET imaging of spinal glial activation after nerve injury in rats," *NeuroImage*, vol. 79, pp. 121–128, 2013.

[34] M. F. Coronel, M. L. S. Granel, M. C. Raggio et al., "Temporal changes in the expression of the translocator protein TSP0 and the steroidogenic enzyme 5α-reductase in the dorsal spinal cord of animals with neuropathic pain: effects of progesterone administration," *Neuroscience Letters*, vol. 624, pp. 23–28, 2016.

[35] X. M. Li, J. Meng, L. T. Li et al., "Effect of ZBD-2 on chronic pain, depressive-like behaviors, and recovery of motor function following spinal cord injury in mice," *Behavioural Brain Research*, vol. 322, pp. 92–99, 2017.

[36] M. F. Coronel, F. Labombarda, A. F. De Nicola, and S. L. Gonzalez, "Progesterone reduces the expression of spinal cyclooxygenase-2 and inducible nitric oxide synthase and prevents allodynia in a rat model of central neuropathic pain," *European Journal of Pain*, vol. 18, no. 3, pp. 348–359, 2014.

[37] M. F. Coronel, M. C. Raggio, N. S. Adler, A. F. De Nicola, F. Labombarda, and S. L. Gonzalez, "Progesterone modulates pro-inflammatory cytokine expression profile after spinal cord injury: implications for neuropathic pain," *Journal of Neuroimmunology*, vol. 292, pp. 85–92, 2016.

[38] K. Tanabe, O. Kozawa, and H. Iida, "Midazolam suppresses interleukin-1β-induced interleukin-6 release from rat glial cells," *Journal of Neuroinflammation*, vol. 8, no. 1, p. 68, 2011.

[39] D. Fang, L. Y. Kong, J. Cai et al., "Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK/PI3K signaling pathway: roles in the development of bone cancer pain in a rat model," *Pain*, vol. 156, no. 6, pp. 1124–1144, 2015.

[40] J. H. Park, Y. H. Seo, J. H. Jang, C. H. Jeong, S. Lee, and B. Park, "Asiatic acid attenuates methamphetamine-induced neuroinflammation and neurotoxicity through blocking of NF-kB/STAT3/ERK and mitochondria-mediated apoptosis pathway," *Journal of Neuroinflammation*, vol. 14, no. 1, p. 240, 2017.

[41] J. W. Lee, L. E. Kim, H. J. Shim et al., "A translocator protein 18 kDa ligand, Ro5-4864, inhibits ATP-induced NLRP3 inflammasome activation," *Biochemical and Biophysical Research Communications*, vol. 474, no. 3, pp. 587–593, 2016.

[42] L. R. Watkins, D. Martin, P. Ulrich, K. J. Tracey, and S. F. Maier, "Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat," *Pain*, vol. 71, no. 3, pp. 225–235, 1997.

[43] A. Gajtko, E. Bakk, K. Hegedus, L. Ducza, and K. Hollo, "IL-1β induced cytokine expression by spinal astrocytes can play a role in the maintenance of chronic inflammatory pain," *Frontiers in Physiology*, vol. 11, article 543331, 2020.

[44] D. S. DalBo, G. M. Nardi, P. Ferrara, R. M. Ribeiro-do-Valle, and R. C. Farges, "Antinociceptive effects of peripheral benzodiazepine receptors," *Pharmacology*, vol. 70, no. 4, pp. 188–194, 2004.

[45] B. Becher, S. Spath, and J. Goverman, "Cytokine networks in neuroinflammation," *Nature Reviews. Immunology*, vol. 17, no. 1, pp. 49–59, 2017.

[46] H. Wilms, J. Claasen, C. Röhl, J. Sievers, G. Deuschl, and R. Lucas, "Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro," *Neurobiology of Disease*, vol. 14, no. 3, pp. 417–424, 2003.

[47] T. Bordet, B. Buissson, M. Michaud et al., "Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy," *The Journal of Pharmacology and Experimental Therapeutics*, vol. 326, no. 2, pp. 623–632, 2008.

[48] V. Papadopoulos and L. Lecanu, "Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma," *Experimental Neurology*, vol. 219, no. 1, pp. 53–57, 2009.

[49] E. Kosek, S. Martinsen, B. Gerdle et al., "The translocator protein gene is associated with symptom severity and cerebral pain processing in fibromyalgia," *Brain, Behavior, and Immunity*, vol. 58, pp. 218–227, 2016.

[50] B. Xiong, G. Jin, Y. Xu et al., "Identification of koumine as a translocator protein 18 kDa positive allosteric modulator for the treatment of inflammatory and neuropathic pain," *Frontiers in Pharmacology*, vol. 12, article 692917, 2021.

[51] E. Lloyd-Evans and H. Waller-Evans, "Biobehavioural and signalling functions of central and peripheral nervous system neurosteroids in health and disease," *Essays in Biochemistry*, vol. 64, no. 3, pp. 591–606, 2020.

[52] V. Sheibani, M. A. Razijadeh, M. A. Bejeshk et al., "The effects of neurosteroid allopregnanolone on synaptic dysfunction in the hippocampus in experimental parkinsonism rats: an electrophysiological and molecular study," *Neuropeptides*, vol. 92, article 102229, 2022.

[53] D. S. Reddy, "Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy," *Frontiers in Endocrinology*, vol. 2, article 38, 2011.

[54] V. Papadopoulos, J. Liu, and M. Culty, "Is there a mitochondrial signaling complex facilitating cholesterol import?," *Molecular and Cellular Endocrinology*, vol. 265, pp. 59–64, 2007.

[55] D. Matsui, M. Sakari, T. Sato et al., "Transcriptional regulation of the mouse steroid 5α-reductase type II gene by..."
progesterone in brain,” *Nucleic Acids Research*, vol. 30, no. 6, pp. 1387–1393, 2002.

[56] M. Zhang, J. Liu, M. M. Zhou et al., “Elevated neurosteroids in the lateral thalamus relieve neuropathic pain in rats with spared nerve injury,” *Neuroscience Bulletin*, vol. 32, no. 4, pp. 311–322, 2016.

[57] N. B. Finnerup, R. Kuner, and T. S. Jensen, “Neuropathic pain: from mechanisms to treatment,” *Physiological Reviews*, vol. 101, no. 1, pp. 259–301, 2021.

[58] IASP IASP, “Taxonomy,” 2019https://www.iasp-pain.org/taxonomy?navItemNumber=576.

[59] E. Cavalli, S. Mammana, F. Nicoletti, P. Bramanti, and E. Mazzon, “The neuropathic pain: an overview of the current treatment and future therapeutic approaches,” *International Journal of Immunopathology and Pharmacology*, vol. 33, article 205873841983838, 2019.

[60] J. N. Campbell and R. A. Meyer, “Mechanisms of neuropathic pain,” *Neuron*, vol. 52, no. 1, pp. 77–92, 2006.

[61] Y. Q. Zhou, Z. Liu, Z. H. Liu et al., “Interleukin-6: an emerging regulator of pathological pain,” *Journal of Neuroinflammation*, vol. 13, no. 1, pp. 1–9, 2016.

[62] R. Shiao and C. A. Lee-Kubli, “Neuropathic pain after spinal cord injury: challenges and research perspectives,” *Neurotherapeutics*, vol. 15, no. 3, pp. 635–653, 2018.

[63] J. Y. Lee, H. Y. Choi, B. G. Ju, and T. Y. Yune, “Estrogen alleviates neuropathic pain induced by inhibiting microglia and astrocyte activation,” *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1864, no. 7, pp. 2472–2480, 2018.

[64] G. Deng, “Integrative medicine therapies for pain management in cancer patients,” *Cancer Journal*, vol. 25, no. 5, pp. 343–348, 2019.

[65] S. Liu, W. T. Liu, Y. P. Liu et al., “Blocking EphB1 receptor forward signaling in spinal cord relieves bone cancer pain and rescues analgesic effect of morphine treatment in rodents,” *Cancer Research*, vol. 71, no. 13, pp. 4392–4402, 2011.

[66] S. A. Schug and C. Chandrasena, “Pain management of the cancer patient,” *Expert Opinion on Pharmacotherapy*, vol. 16, no. 1, pp. 5–15, 2015.

[67] R. M. Fink and E. Gallagher, “Cancer pain assessment and measurement,” *Seminars in Oncology Nursing*, vol. 35, no. 3, pp. 229–234, 2019.

[68] Y. Q. Zhou, Z. Liu, H. Q. Liu et al., “Targeting glia for bone cancer pain,” *Expert Opinion on Therapeutic Targets*, vol. 20, no. 11, pp. 1365–1374, 2016.

[69] F. I. F. Gomes, F. Q. Cunha, and T. M. Cunha, “Peripheral nitric oxide signaling directly blocks inflammatory pain,” *Biochemical Pharmacology*, vol. 176, article 113862, 2020.

[70] V. Palada, A. Siddiqah Ahmed, A. Hugo, M. R. Radojcic, C. I. Svensson, and E. Kosek, “Expression of mitochondrial TSPO and FAM173B is associated with inflammation and symptoms in patients with painful knee osteoarthritis,” *Rheumatology (Oxford, England)*, vol. 60, no. 4, pp. 1724–1733, 2021.

[71] T. R. Miller, J. B. Wetter, M. F. Jarvis, and R. S. Bitner, “Spinal microglial activation in rat models of neuropathic and osteoarthritic pain: an autoradiographic study using [3H]PK11195,” *European Journal of Pain*, vol. 17, no. 5, pp. 692–703, 2013.

[72] Z. Hou, Q. Wang, Z. Guo et al., “Gadolinium-conjugated CB86: a novel TSPO-targeting MRI contrast agent for imaging of rheumatoid arthritis,” *Journal of Drug Targeting*, vol. 28, no. 4, pp. 398–407, 2020.

[73] M. K. Chen and T. R. Guilarte, “Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair,” *Pharmacology & Therapeutics*, vol. 118, no. 1, pp. 1–17, 2008.

[74] Q. Lv, D. Xu, J. Ma et al., “Uric acid drives intestinal barrier dysfunction through TSPO-mediated NLRP3 inflammasome activation,” *Inflammation Research*, vol. 70, no. 1, pp. 127–137, 2021.

[75] K. R. Bae, H. J. Shim, D. Balu, S. R. Kim, and S. W. Yu, “Translocator protein 18 kDa negatively regulates inflammation in microgila,” *Journal of Neuroimmune Pharmacology*, vol. 9, no. 3, pp. 424–437, 2014.

[76] J. Gong, E. M. Szego, A. Leonov et al., “Translocator protein ligand protects against neurodegeneration in the MPTP mouse model of Parkinsonism,” *The Journal of Neuroscience*, vol. 39, no. 19, pp. 3752–3769, 2019.